Article Per Year (5 Year)
p-Index From 2020 - 2025
0
P-Index
This Author published in this journals
All Journal Cermin Dunia Kedokteran Journal of General-Procedural Dermatology & Venereology Indonesia
Anissa, Lidwina
Unknown Affiliation
Health Professions Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Herpes Zoster Fasialis pada Anak Usia 16 Bulan Anissa, Lidwina; Wulandari, Niken; Saulina Siregar, Martha; Arifin, Elly D.
Cermin Dunia Kedokteran Vol 44, No 1 (2017): Nutrisi
Publisher : PT. Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (267.285 KB) | DOI: 10.55175/cdk.v44i1.808

Abstract

Herpes zoster (HZ) merupakan penyakit neurokutan yang disebabkan oleh virus varisela zoster (VVZ). Penyakit ini umumnya mengenai dewasa muda dan jarang pada usia dini. Pajanan terhadap VVZ dalam kandungan atau pada periode awal kelahiran merupakan faktor utama kejadian HZ usia dini. Artikel ini melaporkan satu kasus HZ pada anak laki-laki berusia 16 bulan yang sedang dalam pengobatan penyakit tuberkulosis (TB). Terdapat riwayat cacar air ibu saat usia kehamilan 12 minggu. Kasus ini menggambarkan bahwa varisela maternal pada masa kehamilan dan status imunokompromais pada anak setelah dilahirkan dapat menjadi pemicu reaktivasi VVZ. Pengobatan antiviral yang adekuat serta penatalaksanaan multidisiplin dapat mempercepat kesembuhan.Herpes zoster (HZ) is a neurocutaneous disease caused by varicella zoster virus (VZV). The disease is usually found in adult and rarely in early ages. Exposure to VZV in utero or during the first months of life is the main risk factor for the development of herpes zoster in early ages. This article reported HZ in a 16-month-old boy who is also under tuberculosis treatment. Maternal varicella was found in 12th week of pregnancy. This case described maternal varicella during pregnancy and immunocompromised condition may trigger dormant VZV’s reactivation in dorsal root and cranial nerve. Adequate antiviral therapy and multi-discipline management were needed to provide holistic treatment to hasten recovery. 
Efficacy of inosine pranobex as an adjuvant oral therapy in anogenital warts: an evidence-based case report Nelson, Benny; Sastrini, Indina; Anissa, Lidwina; Manalu, Patricsia; Fourina, Peppy; Kuraga, Rahmaniar Desianti; Indriatmi, Wresti
Journal of General - Procedural Dermatology & Venereology Indonesia Vol. 3, No. 2
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Background: Human papillomavirus (HPV) causes the most prevalent sexually transmitted infection and is an important etiological factor in genital cancer. HPV infection manifests in broad spectrum, from genital warts to cervical intraepithelial neoplasia and cancers. Genital warts remain a frequent problem in primary care. Current modalities provide unsatisfactory result in curing genital warts completely. To date, there are many convincing studies encouraging oral inosine pranobex as an adjuvant therapy to improve post-conventional therapy cure-rate. Aim: To assess the efficacy of inosine pranobex as an adjuvant oral therapy in anogenital warts. Methods: Literature search was performed using Pubmed, Ebsco and Science Direct database. Inclusion criteria were human subjects, randomized controlled trial on patients with genital warts, and inosine pranobex as adjuvant therapy. The studies were appraised and findings were formulated to find the best evidence for collating recommendations in treating genital warts patients. Results: There were three articles related to the clinical questions. All articles were found to be valid after selection based on exclusion and inclusion criteria. Discussion: All articles recommended the addition of oral inosine pranobex as an adjuvant therapy in treating patient with genital warts. Based on the critical appraisal performed previously, addition of oral inosine pranobex may minimize conventional therapy failure. Conclusion: Based on the best evidence available, we would recommend the addition of oral inosine pranobex as adjuvant for treating genital warts, except in special conditions, such as for patients with financial problem as this therapy was not covered by national health insurance.
Co-Authors Arifin, Elly D. Fourina, Peppy Kuraga, Rahmaniar Desianti Manalu, Patricsia Nelson, Benny Niken Wulandari Sastrini, Indina Saulina Siregar, Martha Wresti Indriatmi B. Makes